On February 4, 2011
Insider Transactions and Delayed Disclosure: How a Diabetes “Blockbuster” Blew Up
The timeline of MannKind’s recent failure to get its inhaled insulin product approved is a primer in how not to release bad news about your company.
No tags for this post.
0 Comments